Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Calcitonin 30742X Clinical Use • Diagnose and monitor medullary thyroid carcinoma Reference Range Men Women pg/mL ≤10 ≤5 Children <6 mo* 6 mo-3 y* 3-17 y ≤41 ≤14 ≤6 *From Clin Chem. 2004;50:1828-1829. • Medullary carcinoma of the thyroid (1/3 have normal basal levels and require provocative test to reveal abnormal levels) • Lung, breast, pancreatic cancer (some patients) • Pancreatitis • Thyroiditis • Renal failure • Zollinger-Ellison syndrome • Pernicious anemia • Pregnancy (term) • Newborn infants Method • Immunochemiluminometric assay (ICMA) • Analytical sensitivity: 2 pg/mL • Thyroid agenesis Specimen Requirements 1.0 mL frozen serum 0.5 mL minimum No additive red top Overnight fasting is preferred. 39 Alphabetical Test Section Clinical Background Calcitonin is a 32-amino acid polypeptide produced by parafollicular or C cells in the thyroid. Secretion of calcitonin is stimulated by calcium. Calcitonin decreases osteoclastic bone resorption, but the physiological role in man is uncertain. Calcitonin measurement is indicated for the diagnosis and follow-up of patients with medullary thyroid carcinoma (MTC), the majority of whom produce the hormone. Settings in which the test is appropriate include 1) thyroid nodule in patients with symptoms potentially attributable to hypercalcitoninemia, 2) screening of individuals in families with known or suspected MTC or the multiple endocrine neoplasia syndrome types IIa or IIb, and 3) follow-up of patients with known MTC. Screening family members with normal basal calcitonin levels should include additional calcitonin measurements after pentagastrin and/or calcium stimulation (see Dynamic Tests).